PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsBempegaldesleukin
Bempegaldesleukin
Bempegaldesleukin is a protein pharmaceutical. It is currently being investigated in clinical studies. It is known to target interleukin-2 receptor subunit beta.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
21 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MelanomaD0085453225
Renal cell carcinomaD002292EFO_00003763214
CarcinomaD002277C80.03214
RecurrenceD012008122
Urinary bladder neoplasmsD001749C67112
Head and neck neoplasmsD006258212
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80334
Squamous cell carcinoma of head and neckD000077195233
SarcomaD012509233
Prostatic neoplasmsD011471C61212
Non-small-cell lung carcinomaD002289222
Triple negative breast neoplasmsD064726222
LymphomaD008223C85.9212
Urologic neoplasmsD014571C64-C68111
Breast neoplasmsD001943EFO_0003869C50111
Stomach neoplasmsD013274EFO_0003897C16111
Show 13 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Castration-resistant prostatic neoplasmsD06412911
Non-hodgkin lymphomaD008228C85.911
Covid-19D00008638211
Coronavirus infectionsD018352EFO_0007224B34.211
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBempegaldesleukin
INNbempegaldesleukin
Description
Bempegaldesleukin (development code NKTR-214) is an experimental anti-cancer drug candidate. It is a PEGylated interleukin-2 (IL-2) acting as a CD122-preferential IL-2 pathway agonist designed to activate and proliferate CD8+ T cells and NK cells. It is being developed by Nektar Therapeutics.
Classification
Protein
Drug classinterleukins: interleukin-2 analogues and derivatives; PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID1939126-74-5
RxCUI
ChEMBL IDCHEMBL4298058
ChEBI ID
PubChem CID
DrugBankDB15140
UNII IDBNO1JG5MZC (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
IL2RB
IL2RB
Organism
Homo sapiens
Gene name
IL2RB
Gene synonyms
IL15RB
NCBI Gene ID
Protein name
interleukin-2 receptor subunit beta
Protein synonyms
CD122, CD122 antigen, high affinity IL-2 receptor beta subunit, High affinity IL-2 receptor subunit beta, IL-2 receptor subunit beta, IL-2R subunit beta, IL-2RB, interleukin 15 receptor, beta, interleukin 2 receptor, beta, Interleukin-15 receptor subunit beta, p70-75, p75
Uniprot ID
Mouse ortholog
Il2rb (16185)
interleukin-2 receptor subunit beta (Q3TZT2)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 702 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
193 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use